Aurobindo Pharma Ltd.
Pharma · NSE
52-week range
₹1,016 – ₹1,513
From 52w high
-1.7%
RSI (14)
71.2
vs SMA 50 / 200
↑ 50 · ↑ 200
Aurobindo Pharma trades at Rs 1,487.30, up 20.2% over 12 months and 22.64% over the past 3 months, sitting 12.1% above its 50-DMA of Rs 1,325.89 and 25.4% above its 200-DMA of Rs 1,185.99. The stock carries a trailing PE of 24.71 (forward PE 19.43) with a profit margin of 10.51%, 5-year revenue growth of 8.4%, and a debt-to-equity of 22.25 on a rising debt trend. Quality score of 49 ranks it 3rd of 6 among tracked pharma peers.
- ✓Price is 12.1% above the 50-DMA of Rs 1,325.89 and 25.4% above the 200-DMA of Rs 1,185.99, with a 52-week drawdown of only -1.72%, reflecting strong near-term price momentum.
- ✓Forward PE of 19.43 represents compression versus the trailing PE of 24.71, and is below sector peers Apollo Hospitals at 64.58 and Max Healthcare at 69.48, indicating relatively lower earnings-based valuation within the sector.
- ✓Five-year revenue growth of 8.4% alongside earnings growth of 7.6% indicates consistent top-line and bottom-line expansion over the medium term.
- ✓Among 6 tracked pharma peers, AUROPHARMA ranks 3rd on quality score at 49, above Cipla at 30 and Dr. Reddy's at 32, indicating mid-to-upper quality positioning within the peer set.
- ✗Debt-to-equity of 22.25 with a rising debt trend and FCF positive in only 2 of tracked years points to a structurally leveraged balance sheet relative to pharma-sector norms.
- ✗Consistency score of 27 out of 100 and zero years of ROE above 15% in tracked history reflect weak earnings quality and limited durability of returns on equity.
- ✗RSI of 71.24 places the stock in overbought territory following a 22.64% 3-month price increase; nearest identified support levels are Rs 1,240, Rs 1,170, and Rs 1,116 — approximately 17% to 25% below current price.
- ✗Profit margin of 10.51% and a mid-pack quality score of 49 indicate the business has not demonstrated the sustained high-margin profile seen in top-tier pharma names.
- ·Recent news flow across 6 articles is entirely neutral in sentiment; AUROPHARMA appears in multiple stock-watch roundups from Business Today, MSN, and LatestLY without stock-specific fundamental catalysts identified.
- ·The stock has been included alongside names like ITC, Power Grid, and Coal India in broad market stock-watch lists, suggesting attention as part of a broader large-cap rotation rather than company-specific newsflow.
- ·No regulatory, pipeline, or earnings-specific headlines were captured in the news sample; the sparse sample of 6 articles limits the conclusions that can be drawn from sentiment data.
- ?Does the elevated debt-to-equity of 22.25 reflect industry-standard working capital cycles in pharma generics, or does it represent balance-sheet risk that warrants monitoring alongside the rising debt trend?
- ?With FCF positive in only 2 of tracked years and a consistency score of 27, what is the trajectory of free cash flow generation in recent quarters, and has that trend improved or deteriorated?
- ?The stock has risen 22.64% in 3 months with RSI at 71.24 and no resistance levels identified — what historical precedents exist for AUROPHARMA price behavior following extended overbought periods?
- ?Given that ROE data is unavailable for AUROPHARMA and most sector peers, how does the company compare on return-on-capital metrics to its generics-focused peers such as Cipla and Dr. Reddy's over a multi-year period?
PE
24.7
Forward PE
19.4
ROE
—
Profit margin
+10.5%
D/E
22.25
Dividend yield
+0.3%
Quality score
49/100
ROE 5y above 15%
0/5 yrs
FCF 5y positive
2/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 11 May 2026.